For owners of daycare clinics, single specialty chains and diagnostic laboratories. Asset-light, modular models that hold clinical quality while they attract capital and replicate across sites.
Every challenge is tagged to a lens, and every challenge is answered by a named service on this page.
PM-JAY mandates cap procedure rates well below private market realisations - cataract surgery at ₹14,000 against ₹25,000–₹40,000 privately, CABG at ₹1,30,000 against ₹4,00,000+. Only 10–15% of patients are eligible for cashless options, compressing standalone clinic margins by 15–25%.
Source: PM-JAY package rates; UIIC/NHM How we solve thisNearly 70% of super-specialists reside in tier 1 metropolitan areas. Tier 2 and tier 3 markets depend on government-subsidised payer mixes with price controls, where ARPOB drops from ₹4,000–₹8,000 in metros to under ₹1,000 in tier 3 - while talent costs rise sharply outside metro clusters.
Source: NITI Aayog 2023; NHM data How we solve thisSpecialty equipment accounts for 40–60% of total setup costs. Standalone clinics face restricted credit leverage - roughly 0.4× debt multiples against 0.6–0.7× for corporate platforms - limiting their ability to finance expansion and absorb specialised infrastructure costs.
Source: ICRA 2024; lender leverage benchmarks How we solve thisAround 85% of standalone diagnostic centres depend on two or three institutional payers. Government price caps on routine panels - CBC capped at ₹2,500 against ₹5,000–₹7,000 privately, TB PCR at ₹500 against ₹1,500 - squeeze gross margins to 5–10%, with 75–80% of patients paying cash.
Source: NHM 2023; Ayushman Bharat rate schedules How we solve thisDiagnostic equipment procurement accounts for 50–60% of setup capex. Ongoing consumable and reagent costs absorb 35–40% of operational revenue against 25–30% in aggregated platforms, and 90-day reagent inventory demands sizeable working capital reserves.
Source: ICRA 2024; NHM 2023 How we solve thisOnly around 5% of standalone diagnostic centres maintain full-time in-house pathologists; 80% rely on visiting or contract arrangements, creating quality-control bottlenecks and technical turnover of 12–15% annually.
Source: NHM 2024; WHO 2023 How we solve thisThe work is organised across six lenses: innovation, efficiency, marketing and sales, financial structuring, regulation and compliance, and delivery.
Selecting and deploying EHR/LIS platforms with ABDM compliance and interoperability, plus centralised digital reporting and standardised clinical protocols that hold quality constant across every site.
Counters: Pathologist ScarcityClinicians design the programme around a defined catchment population, a clinical endpoint and a measurement plan, turning a funding request into something a CSR committee can approve.
Programme DesignTelemedicine deployment and AI-assisted screening camps for CSR-funded public health programmes reaching tier 2, tier 3 and rural catchments - the same clinical and technical rigour we apply to a funded venture, applied to a funded programme.
Telemedicine · AI ScreeningNetwork architecture that concentrates scarce specialists and heavy equipment at the hub while spokes carry volume - the structural answer to talent scarcity outside metros.
Counters: Geographic Talent ImbalanceClinic flow redesign across scheduling, consultation, procedures and billing to maximise throughput. Time-motion studies and lean process mapping to eliminate the bottlenecks costing revenue daily.
Efficiency & ThroughputVolume-backed procurement, vendor consolidation and shared-platform economics that move reagent, consumable and machinery costs toward the benchmarks aggregated networks enjoy.
Counters: Reagent & Machinery OverheadSpecialty-specific digital strategies - SEO, paid search, social proof and KOL outreach - to build a consistent, trackable patient pipeline with cost-per-acquisition benchmarks.
Growth & RevenueTest-mix and payer-mix rebalancing, insurance and TPA empanelment strategy, and scheme negotiation - reducing exposure to any single reimbursement source.
Counters: Single-Payer DependencyQualified projects taken directly to corporate CSR teams, foundations and family offices with healthcare in their giving mandate, rather than asking donors to go looking.
Donor MatchingCatchment sizing and payer-mix analysis before a lease is signed. We model achievable reimbursement against local demographics so clinical capacity is matched to what the market will actually pay.
Counters: Geographic Talent ImbalanceDeep-dive into EBITDA per chair, suite or bed, supply chain costs and staff utilisation ratios. We identify structural leakages and implement a verified improvement programme with shared-savings accountability.
Counters: Payer Price Cap SqueezeStructuring the equity narrative and financial model for chain expansion, and connecting founders with PE and family office capital that has appetite for asset-light specialty roll-ups.
Counters: Equipment Capex & Credit LimitsPreparing clinics and laboratories for NABH entry-level or full accreditation, NABL and CAP standards, JCI, and insurance empanelment - turning quality into a patient-trust and payer-access advantage.
NABH · NABL · CAP · JCISpecification, procurement, installation, staff training and commissioning for funded capital equipment, so the asset ends up in clinical use rather than in a store room.
Capex · CommissioningSplitting it this way keeps the incentives pointing the right direction. On a raise we carry part of the risk of it not closing. On an operating engagement you are buying our time and method, and you should not pay a premium for that on the back of a transaction that may never happen.
Structuring the equity narrative, preparing the model and data room, and running the investor process.
Site feasibility, hub-and-spoke design, procurement, payer diversification and accreditation readiness.
Where an engagement covers both, the operating work is scoped and priced on its own terms rather than folded into the raise, so you are not paying a transaction rate for advisory hours.
Specialist practices and diagnostic labs that want scale without losing clinical consistency. Let us talk through the model.